A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus - Trial NCT06362265
Access comprehensive clinical trial information for NCT06362265 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 1
Apr 01, 2024
Nov 01, 2026
Primary Outcome
Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3209590,PK: Maximum Observed Plasma Concentration (Cmax) of LY3209590
Summary
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood
 stream after a single dose and how long it takes the body to remove it in pediatric
 participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100
 days.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06362265
Non-Device Trial